Innovative Antibody Pipeline

United BioPharma (UBP) is dedicated to the development and commercialization of proprietary monoclonal antibodies with significant impact to patients. We have established a set of advanced antibody platform technologies in our state-of-the-art Research and Development and Manufacturing facilities based in Hsinchu, Taiwan. Our cGMP manufacturing plant, considered largest in Taiwan, is fully equipped with high-end sophisticated instruments for commercial scale manufacturing.

Our Integrated Technology Platform

UBP possesses high value technology platform: A fully integrated monoclonal antibody (mAb) drug development technology which enables us to generate stable, high productivity, and serum free clones for industrial scale mAb production. Our competitive cell and protein process development, characterization, analytical and formulation method allow us to develop high titer, robust and scalable cell culture and protein fermentation resulting in optimized-yield, high quality and robust purification process for our produced antibodies.

News and Events

News Releases

  • 2022/08/29
    NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
  • 2022/08/02
    United BioPharma announces JCI publication of UB-221 mAb data demonstrating unique profiles of potent IgE neutralization, IgE synthesis reduction, and durable urticaria symptom relief
  • 2022/05/26
    United BioPharma Receives IND Approval from TFDA for A Phase 2 Study of UB-221 in Adults with Chronic Spontaneous Urticaria

Efficiency and Effectiveness: UBP Uses the Power of Innovation to Bring Patients a Better Life

UBP Protein Drug Facility opening (ENG)

Shareholder Briefcase